Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Papp

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Current Problems in Dermatology|August 28, 2009
Monitoring patients treated with efalizumab or alefaceptK A Papp
Clinics in Dermatology|October 1, 1991
Systemic gold therapyK A Papp, N H Shear
Canadian Medical Association Journal|November 1, 1984
Cimetidine-induced psychosis in a 14-year-old girlK A Papp, R M Curtis
Journal of the European Academy of Dermatology and Venereology : JEADV|February 14, 2018
Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disordersM J Gooderham, K A Papp, C W Lynde
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2017
Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasisK A Papp, M J Gooderham, G Girard, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 11, 2018
Response to 'Psoriasis patients' preference for an aerosol foam topical formulation' by Vender R et alC-H Hong, K A Papp, K W Lophaven, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2012
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison studyK A Papp, R Kaufmann, D Thaçi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 11, 2017
Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL studyC-H Hong, K A Papp, K W Lophaven, et al.
The British Journal of Dermatology|June 18, 2019
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasisJ Hercogová, K A Papp, V Chyrok, et al.
The British Journal of Dermatology|November 8, 2021
Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world settingK A Papp, M J Gooderham, L E Albrecht, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Current Problems in Dermatology|August 28, 2009
Monitoring patients treated with efalizumab or alefaceptK A Papp
Clinics in Dermatology|October 1, 1991
Systemic gold therapyK A Papp, N H Shear
Canadian Medical Association Journal|November 1, 1984
Cimetidine-induced psychosis in a 14-year-old girlK A Papp, R M Curtis
Journal of the European Academy of Dermatology and Venereology : JEADV|February 14, 2018
Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disordersM J Gooderham, K A Papp, C W Lynde
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2017
Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasisK A Papp, M J Gooderham, G Girard, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 11, 2018
Response to 'Psoriasis patients' preference for an aerosol foam topical formulation' by Vender R et alC-H Hong, K A Papp, K W Lophaven, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2012
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison studyK A Papp, R Kaufmann, D Thaçi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 11, 2017
Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL studyC-H Hong, K A Papp, K W Lophaven, et al.
The British Journal of Dermatology|June 18, 2019
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasisJ Hercogová, K A Papp, V Chyrok, et al.
The British Journal of Dermatology|November 8, 2021
Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world settingK A Papp, M J Gooderham, L E Albrecht, et al.
Pageof 6